At present, bamlanivimab and etesevimab — the other drug used in the treatment — are not authorized for use in the U.S. due to their diminished efficacy against the omicron variant.
“However, it is the recommendation of the U.S. government that product be retained in the event that future SARS-CoV-2 variants, which may be susceptible to bamlanivimab and etesevimab, emerge and become prevalent in the United States,” HHS said May 4.
Federal health officials are still reviewing whether to extend the shelf life for etesevimab and will provide an update on the matter in November, HHS said.
Learn more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
